STOCK TITAN
  1. Home
  2. Sec-filings
  3. MDXH
  4. [Form 3] MDxHealth SA Initial Statement of Beneficial Ownership

MDxHealth (NASDAQ: MDXH) officer discloses extensive share option awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

MDxHealth SA officer Joseph Sollee filed an initial Form 3 describing his holdings of share options over ordinary shares. The filing lists multiple option grants with varying exercise prices in euros and U.S. dollars, different vesting schedules including performance-based vesting, and expirations extending through 2035.

Positive

  • None.

Negative

  • None.
Insider Sollee Joseph
Role See Remarks
Type Security Shares Price Value
holding Share Option -- -- --
holding Share Option -- -- --
holding Share Option -- -- --
holding Share Option -- -- --
holding Share Option -- -- --
holding Share Option -- -- --
holding Share Option -- -- --
holding Share Option -- -- --
holding Share Option -- -- --
holding Share Option -- -- --
holding Share Option -- -- --
Holdings After Transaction: Share Option — 510,350 shares (Direct)
Footnotes (11)
  1. F1. Represents options to purchase ordinary shares at a price per share of 12.40 Euros granted on May 14, 2019 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 24, 2019. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
  2. F2. Represents options to purchase ordinary shares at a price per share of 8.00 Euros granted on June 24, 2020 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 15, 2020. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
  3. F3. Represents options to purchase ordinary shares at a price per share of 13.75 Euros granted on June 23, 2021 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 3, 2021. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
  4. F4. Represents options to purchase ordinary shares at a price per share of 13.75 Euros granted on June 23, 2021 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 3, 2021. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
  5. F5. Represents options to purchase ordinary shares at a price per share of 6.84 Euros granted on May 12, 2022 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on August 3, 2022. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
  6. F6. Represents options to purchase ordinary shares at a price per share of 6.84 Euros granted on May 12, 2022 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on August 3, 2022. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
  7. F7. Represents options to purchase ordinary shares at a price per share of 2.90 Euros granted on March 21, 2023 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 30, 2023. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
  8. F8. Represents options to purchase ordinary shares at a price per share of 2.90 Euros granted on March 21, 2023 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 30, 2023. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
  9. F9. Represents options to purchase ordinary shares at a price per share of $2.62 granted on February 20, 2024 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 22, 2024. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
  10. F10. Represents options to purchase ordinary shares at a price per share of $2.62 granted on February 20, 2024 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 22, 2024. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the performance periods.
  11. F11. Represents options to purchase ordinary shares at a price per share of $1.47 granted on March 26, 2025 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on April 11, 2025. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
Option grant size 23,000 underlying shares Share option over ordinary shares expiring July 24, 2029
Exercise price 12.40 Euros/share Options granted May 14, 2019; shareholder resolution July 24, 2019
Exercise price 8.00 Euros/share Options granted June 24, 2020; resolution July 15, 2020
Exercise price 13.75 Euros/share Options granted June 23, 2021; resolution July 3, 2021
Exercise price 6.84 Euros/share Options granted May 12, 2022; resolution August 3, 2022
Recent grant size 100,000 underlying shares Options at $2.62/share expiring June 22, 2034
Recent grant size 200,000 underlying shares Options at $1.47/share expiring April 11, 2035
share option financial
"Represents options to purchase ordinary shares at a price per share"
extraordinary general shareholders' meeting regulatory
"issued pursuant to a resolution of an extraordinary general shareholders' meeting"
A meeting of a company's shareholders called outside the regular annual meeting to decide urgent or special matters that cannot wait for the annual gathering. Like an emergency town hall, it is used to vote on significant issues such as large mergers, changes to the board, amendments to corporate bylaws, or major financing decisions, and it matters to investors because the outcomes can quickly change a company’s strategy, ownership structure, or financial prospects.
vesting financial
"The options vest in three equal installments on each of the first three anniversaries"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
performance criteria financial
"vested upon the achievement of certain Company performance criteria evaluated by the Board"
underlying ordinary shares financial
"Represents options to purchase ordinary shares at a price per share"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →

FAQ

What does the MDXH Form 3 filing by Joseph Sollee report?
The Form 3 for MDxHealth SA (MDXH) reports officer Joseph Sollee’s existing share option holdings. It lists several option grants over ordinary shares, detailing exercise prices, vesting conditions, and expiration dates, but does not show any recent purchases or sales.

What share options does Joseph Sollee hold in MDxHealth SA (MDXH)?
Joseph Sollee holds multiple share options over MDxHealth ordinary shares. Individual grants include underlying share amounts such as 23,000, 20,000, 65,000, 100,000, and 200,000 ordinary shares, each tied to specific grant dates, exercise prices, vesting schedules, and expiration dates.

What are some exercise prices for Joseph Sollee’s MDXH options?
The filing shows exercise prices including 12.40 Euros, 8.00 Euros, 13.75 Euros, and 6.84 Euros for earlier grants, plus $2.62 and $1.47 per share for more recent awards, each associated with its respective grant and shareholder meeting approval dates.

How do Joseph Sollee’s MDXH options vest according to the Form 3?
Some options vest in three equal installments on each of the first three anniversaries of the grant date. Other grants vest upon achieving specified company performance criteria evaluated by MDxHealth’s Board of Directors at the end of defined performance periods.

When do Joseph Sollee’s MDXH share options expire?
The reported share options have expiration dates ranging from July 24, 2029 through April 11, 2035. Each grant lists a specific expiration date, reflecting the long-term nature of Sollee’s incentive awards tied to MDxHealth ordinary shares.
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Sollee Joseph
(Last)(First)(Middle)
CAP BUSINESS CENTER
ZONE INDUSTRIELLE DES HAUTS-SARTS
(Street)
HERSTALBELGIUM4040
(City)(State)(Zip)
BELGIUM
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
MDxHealth SA [ MDXH ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share Option (1)07/24/2029Ordinary Shares23,000(1)D
Share Option (2)07/15/2030Ordinary Shares7,350(2)D
Share Option (3)07/03/2031Ordinary Shares17,500(3)D
Share Option (4)07/03/2031Ordinary Shares17,500(4)D
Share Option (5)08/03/2032Ordinary Shares20,000(5)D
Share Option (6)08/03/2032Ordinary Shares20,000(6)D
Share Option (7)06/30/2033Ordinary Shares20,000(7)D
Share Option (8)06/30/2033Ordinary Shares20,000(8)D
Share Option (9)06/22/2034Ordinary Shares100,000$2.62D
Share Option (10)06/22/2034Ordinary Shares65,000$2.62D
Share Option (11)04/11/2035Ordinary Shares200,000$1.47D
Explanation of Responses:
1. Represents options to purchase ordinary shares at a price per share of 12.40 Euros granted on May 14, 2019 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 24, 2019. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
2. Represents options to purchase ordinary shares at a price per share of 8.00 Euros granted on June 24, 2020 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 15, 2020. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
3. Represents options to purchase ordinary shares at a price per share of 13.75 Euros granted on June 23, 2021 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 3, 2021. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
4. Represents options to purchase ordinary shares at a price per share of 13.75 Euros granted on June 23, 2021 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on July 3, 2021. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
5. Represents options to purchase ordinary shares at a price per share of 6.84 Euros granted on May 12, 2022 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on August 3, 2022. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
6. Represents options to purchase ordinary shares at a price per share of 6.84 Euros granted on May 12, 2022 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on August 3, 2022. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
7. Represents options to purchase ordinary shares at a price per share of 2.90 Euros granted on March 21, 2023 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 30, 2023. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
8. Represents options to purchase ordinary shares at a price per share of 2.90 Euros granted on March 21, 2023 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 30, 2023. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the relevant performance periods.
9. Represents options to purchase ordinary shares at a price per share of $2.62 granted on February 20, 2024 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 22, 2024. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
10. Represents options to purchase ordinary shares at a price per share of $2.62 granted on February 20, 2024 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on June 22, 2024. The options vested upon the achievement of certain Company performance criteria evaluated by the Board of Directors at the end of the performance periods.
11. Represents options to purchase ordinary shares at a price per share of $1.47 granted on March 26, 2025 and issued pursuant to a resolution of an extraordinary general shareholders' meeting on April 11, 2025. The options vest in three equal installments on each of the first three anniversaries of the date of grant.
Remarks:
Executive Vice President of Corporate Development and General Counsel
/s/ Mark Busch, as attorney-in-fact for Joseph Sollee04/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR